Summary

Europe Biopsy Device Market Size & Summary

Europe Biopsy Device market is expected to reach US$ 1,137.2 million by 2033 from US$ 672.6 million in 2024, with a CAGR of 6.01% from 2025 to 2033. The increasing need for sophisticated, affordable, and adaptable solutions that improve operational efficiency is propelling the market. The market expansion in Europe is also being supported by the growing demand for minimally invasive procedures, adherence to stringent regulations, technological developments in imaging and automation, and a growing focus on early cancer detection and preventive healthcare, which guarantees quicker and more precise diagnoses.

The report Europe Biopsy Devices Market & Forecast covers by Product Biopsy (Needle Based Devices, Forceps, Localization Wire, and Others Products), Imaging Technology (CT scan, Stereotactic Guided, Ultrasound Guided, MRI Guided, and Others), End-User (Hospital and Clinics, Diagnostics Laboratories, and Other), Country and Company Analysis 2025-2033.


Europe Biopsy Device Industry Overview

The increasing incidence of cancer, technical developments, and a growing focus on early diagnosis and minimally invasive procedures are all contributing to the continuous expansion of the biopsy instrument market in Europe. Breast, prostate, and lung cancers are among the many cancers that can be detected by biopsy equipment, which are used to remove tissue samples for diagnostic examination. The need for precise diagnostic tools has increased as cancer rates in Europe continue to grow, primarily as a result of aging populations and lifestyle factors. Furthermore, advancements in biopsy methods including image-guided biopsy, fine-needle aspiration, and core needle biopsy are improving the accuracy and efficacy of diagnoses. The market for biopsy devices has grown as a result of these advancements.

Further expansion is being fueled by the growing use of automated and robotically assisted biopsy technologies. Both patients and healthcare professionals find these technologies more appealing since they give more accuracy, shorter operation times, and less patient discomfort. Additional drivers of market expansion include the expanding number of cutting-edge healthcare facilities and encouraging government initiatives to provide access to healthcare. Europe has a well-established healthcare system and a high degree of medical knowledge, which fosters the adoption of innovative biopsy technology. Driven by technological innovation and growing healthcare requirements, the biopsy device business in Europe is expected to continue its upward trajectory as the demand for diagnostic procedures increases and healthcare practitioners look for more precise and efficient ways.

The region's high cancer case prevalence is probably going to contribute to the market's expansion. For example, according to Globocan 2020, there were a projected 531,000 new instances of breast cancer in Europe in 2020; by 2040, that figure is predicted to rise to 568,000. Additionally, the same source claims that of all the cancer forms, breast cancer is the most prevalent.


Growth Drivers for the Europe Biopsy Device Market

Raising Knowledge of Early Diagnosis

A major cultural change toward proactive healthcare is being driven by public awareness campaigns and healthcare programs throughout Europe that highlight the significance of early cancer identification. Early diagnosis enables therapy to start earlier, which frequently improves patient survival rates and quality of life. The frequency of biopsies performed to confirm or rule out illnesses has also increased as more people are seeking medical examinations earlier. Because biopsy procedures are essential for making quick and accurate diagnoses, the emphasis on preventive healthcare and early intervention is driving up demand for them. Access to modern diagnostic services is also being facilitated by increased government funding and support for public health initiatives.

Furthermore, the demand for accurate, dependable, and minimally invasive biopsy technologies is being reinforced throughout Europe by the increased awareness among patients and medical professionals of the long-term advantages of early detection. According to the 2024 article, the European Commission showcased its efforts during the European Week Against Cancer (May 25–31), emphasizing the EU’s Beating Cancer Plan, which focuses on prevention, early identification, and treatment. Addressing inequities, sophisticated cancer imaging, and the #GetScreenedEU campaign are important initiatives. The initiative, which has €4 billion behind it, encourages innovation and better patient care.


Increasing Focus on Accuracy and Efficiency in Medical Procedures

The expansion is being driven by the growing emphasis on optimizing clinical operational efficiency and simplifying healthcare processes. The growing need for sophisticated, adaptable solutions that improve workflow effectiveness is consistent with the larger trend of healthcare optimization. The introduction of integrated biopsy systems and kits, which provide streamlined methods for diagnostic and interventional treatments, is being driven by the need for time-saving, cost-effective instruments. Furthermore, the development and approval of novel biopsy technologies are being promoted by adherence to strict regulatory criteria. This increases the gadgets' legitimacy and uptake by guaranteeing that they fulfill strict safety and performance requirements.

For example, SYNDEO Medical declared in 2024 that its SYNDEOPack Interventional Procedure PacksTM and Xssential Rapid Delivery Procedure PacksTM have received European Medical Device Regulation (MDR) clearance. Soft tissue biopsy devices and other biopsy tools intended to improve surgical and interventional procedures are included in these procedure packs. For medical practitioners, the flexible packets offer reduced expenses, less packing, and more process effectiveness.


Microtransactions and In-Game Purchases

The development of automated systems and advanced imaging technologies, among other advancements in biopsy equipment, is significantly driving market expansion. Because of their accuracy, ease of use, and ability to produce findings quickly, instruments including robotic-assisted biopsy systems, liquid biopsy techniques, and ultrasound-guided biopsy needles are growing in popularity in Europe. By enabling more precise tissue sample collection, these technological advancements help medical professionals reduce problems, speed up recovery, and increase diagnostic accuracy. By improving targeting precision and enabling real-time decision-making during treatments, artificial intelligence (AI) in robotics and imaging is improving the biopsy process. Additionally, the industry is moving toward innovations that improve patient outcomes and lessen discomfort due to the growing desire for minimally invasive procedures.


In 2024, the Brevera Breast Biopsy System with a 7-gauge needle was released in Europe by Hologic, Inc. This new improvement enhances the system's capabilities and makes it possible for radiologists to obtain larger tissue samples more quickly, thus reducing patient discomfort and procedure time. The solution makes it easier to integrate with existing biopsy guidance systems, which improves breast imaging operations.


Challenges in the Europe Biopsy Device Market

Inconsistent Healthcare Access

Even while Europe's healthcare system is typically strong, access to sophisticated diagnostic instruments, such biopsy devices, varies greatly, especially in rural areas and in nations with weaker healthcare budgets. Early diagnostic services may not be as readily available in less affluent areas since hospitals and clinics may find it difficult to purchase state-of-the-art technology. Furthermore, the expense of running and maintaining sophisticated biopsy equipment may prevent their broad use in public health systems. It is difficult to deliver consistent, high-quality healthcare in every location as a result of this unequal resource distribution. Delays in diagnosis and treatment consequently affect underprivileged areas, which restricts the market potential for biopsy equipment in these areas and slows the growth of the sector as a whole.


Competition and Price Sensitivity

With multiple manufacturers offering a broad range of equipment, from sophisticated robotic-assisted systems to conventional manual tools, the European biopsy device industry is quite competitive. In addition to spurring innovation, this rivalry puts pressure on prices, especially in public healthcare systems with limited funding. Price sensitivity is a major issue since hospitals and clinics frequently choose less expensive options over high-end goods, particularly in areas with different economies. Even though cutting-edge biopsy technologies increase efficiency and accuracy, their high upfront costs and continuing maintenance requirements may prevent widespread adoption. Therefore, price sensitivity may restrict the adoption of expensive equipment, impacting the market's potential for growth and making it more difficult for some healthcare settings to access state-of-the-art diagnostic instruments.


Needle-based biopsy devices offer precision, efficiency, and minimal invasiveness

Needle-based biopsy devices are among the leading products in the Europe biopsy devices market. This is because they effectively obtain tissue samples for accurate analysis. These gadgets offer minimally invasive approaches, decreasing patient discomfort and recuperation time. With the rising demand for precise and efficient biopsy techniques, healthcare professionals and European patients prefer needle-based biopsy devices.


Europe Biopsy Device Market Overview by Regions

By countries, the Europe Biopsy Device market is divided into United Kingdom, France, Germany, Italy, Spain, Russia and Rest of Europe.


United Kingdom Biopsy Device Market

The market for biopsy devices in the UK is expanding due to improvements in minimally invasive technology and rising demand for early cancer detection. The UK is a major market for biopsy instruments due to its robust healthcare system and high cancer diagnosis rate, especially for lung, prostate, and breast cancers. The market is dominated by needle-based biopsy methods, such as core needle and fine-needle aspiration, which provide accuracy and less discomfort for patients. Due to their increased accuracy and shorter operation times, robotic-assisted and image-guided biopsies are also driving market expansion. The National Health Service (NHS) is also crucial in increasing access to biopsy procedures, but the use of high-end equipment may be hampered by financial limitations and legal issues. All things considered; the UK continues to be a major force in the European biopsy device business.

The need for biopsies is anticipated to rise in the UK due to the rising number of cancer cases. For example, blood cancer is the fifth most frequent malignancy in the UK, with over 41,000 new cases identified annually, according to data published by Blood Cancer UK in August 2022. According to the same source, there are roughly 250,000 blood cancer patients in the UK. According to the same source, blood cancer is the most prevalent type of childhood cancer, with one in 16 men and one in 22 women at risk of developing it at some time in their lives.

Additionally, it reported that around 500 children under the age of 15 receive a blood cancer diagnosis each year, with approximately 400 of them having pediatric leukemia and 100 having lymphoma. Additionally, throughout the anticipated period, the growth of biopsy instruments would be positively impacted by advanced healthcare infrastructure and the rising incidence of infections.


France Biopsy Device Market

The market for biopsy devices in France is developing due to an increase in cancer cases and a need for less intrusive methods of early diagnosis. France is a major European market for biopsy instruments, especially for the detection of lung, prostate, and breast cancers, thanks to its highly developed healthcare system and rigorous diagnostic standards. Because of their precision and low level of patient discomfort, needle-based biopsy procedures including core needle and fine-needle aspiration are frequently employed. Furthermore, advancements in robotic-assisted and image-guided biopsy technologies are becoming more popular, increasing accuracy and cutting down on operation times. The market is confronted with obstacles like the high price of cutting-edge technologies and inconsistent reimbursement practices, which could restrict the uptake of high-end gadgets. With ongoing improvements in medical technology, the industry is still expected to grow.


Germany Biopsy Device Market

The market for biopsy devices in Germany is expanding steadily due to increased cancer rates, especially in lung, prostate, and breast malignancies, as well as a strong demand for least invasive diagnostic methods. The adoption of cutting-edge biopsy equipment is facilitated by Germany's well-established healthcare system and high degree of medical knowledge. Because of their accuracy and patient-friendliness, needle-based biopsy techniques like core needle and fine-needle aspiration continue to be the most popular. Furthermore, robotic-assisted and image-guided biopsy technologies are becoming more and more popular because to their improved accuracy and faster recovery periods. The public healthcare sector's cost concerns and reimbursement issues may hinder the widespread adoption of high-end biopsy systems, even in the face of the growing need for sophisticated instruments. However, Germany continues to be one of Europe's most important markets for biopsy equipment.


Italy Biopsy Device Market

The market for biopsy devices in Italy is expanding steadily due to rising cancer rates and improvements in diagnostic technology. Early cancer identification, especially for lung, prostate, and breast cancers, is becoming more and more important in Italy's healthcare system, which provides a combination of public and private healthcare options. Because of their accuracy and low level of invasiveness, needle-based biopsy methods like core needle and fine-needle aspiration remain popular. Furthermore, advancements in robotic-assisted and image-guided biopsy tools are becoming more popular, leading to better patient outcomes and diagnostic accuracy. However, geographical differences in healthcare access and price sensitivity, especially in public healthcare systems, may prevent the widespread use of high-end biopsy tools. Notwithstanding these obstacles, the Italian market exhibits a great deal of development potential consistent with general European trends.


Europe Biopsy Devices Market Segments

Product – Market breakup in 4 viewpoints:
1. Needle Based Biopsy Devices
2. Biopsy Forceps
3. Localization Wire
4. Others Products


Imaging Technology – Market breakup in 5 viewpoints:
1. CT scan
2. Stereotactic Guided
3. Ultrasound Guided
4. MRI Guided
5. Others


End-User – Market breakup in 3 viewpoints:
1. Hospital and Clinics
2. Diagnostics Laboratories
3. Other


Country – Market breakup of 5 Countries:
1. United Kingdom
2. France
3. Germany
4. Italy
5. Spain
6. Russia
7. Rest of Europe


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. Becton, Dickinson and Company
2. Thermo Fisher Scientific Inc.
3. Bio-Rad Laboratories
4. Exact Sciences (Genomic Health)
5. Biocept
6. Roche Diagnostics
7. Myriad Genetics Inc.
8. Qiagen
9. NeoGenomics Laboratories
10. Quest Diagnostics Inc.


Key Questions Answered in Report:
1. How big is the Europe Biopsy Device industry?
The Europe Biopsy Device market size was valued at US$ 672.6 million in 2024 and is expected to reach US$ 1,137.2 million in 2033.

2. What is the Europe Biopsy Device growth rate?
The Europe Biopsy Device market is expected to expand at a compound annual growth rate (CAGR) of 6.01% from 2025 to 2033.

3. Who are the key players in Europe Biopsy Device industry?
Some key players operating in the Europe Biopsy Device market includes Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Exact Sciences (Genomic Health), Biocept, Roche Diagnostics, Myriad Genetics Inc., Qiagen, NeoGenomics Laboratories, and Quest Diagnostics Inc.

4. What are the factors driving the Europe Biopsy Device industry?
Innovations in robotic-assisted and precision biopsy techniques, aging populations, improved healthcare infrastructure, rising cancer prevalence, growing demand for early diagnosis, and regulatory support are the main factors driving the biopsy device market in Europe.

5. Which Country held the largest market share in the Europe Biopsy Device industry?
United Kingdom is expected to hold the largest market share in the industry.

6. What segments are covered in the Europe Biopsy Device Market report?
Product, Imaging Technology, End User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research & Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Europe Biopsy Device Market


6. Market Share
6.1 By Products
6.2 By Imaging Technology
6.3 By County
6.4 By End User


7. Product
7.1 Needle Based Biopsy Devices
7.2 Biopsy Forceps
7.3 Localization Wire
7.4 Others Products


8. Imaging Technology
8.1 CT Scan
8.2 Stereotactic Guided
8.3 Ultrasound Guided
8.4 Mri Guided
8.5 Others


9. Country
9.1 United Kingdom
9.2 France
9.3 Germany
9.4 Italy
9.5 Spain
9.6 Russia
9.7 Rest of Europe


10. End User
10.1 Hospital and Clinics
10.2 Diagnostics Laboratories
10.3 Other


11. Porter's Five Forces Analysis
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Competition
11.4 Threat of New Entrants
11.5 Threat of Substitutes


12. SWOT Analysis
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threats


13. Key Players Analysis
13.1 Becton, Dickinson and Company
13.1.1 Overview
13.1.2 Recent Developments
13.1.3 Revenue

13.2 Thermo Fisher Scientific Inc.
13.2.1 Overview
13.2.2 Recent Developments
13.2.3 Revenue

13.3 Bio-Rad Laboratories
13.3.1 Overview
13.3.2 Recent Developments
13.3.3 Revenue

13.4 Exact Sciences (Genomic Health)
13.4.1 Overview
13.4.2 Recent Developments
13.4.3 Revenue

13.5 Biocept
13.5.1 Overview
13.5.2 Recent Developments
13.5.3 Revenue

13.6 Roche Diagnostics
13.6.1 Overview
13.6.2 Recent Developments
13.6.3 Revenue

13.7 Myriad Genetics Inc.
13.7.1 Overview
13.7.2 Recent Developments
13.7.3 Revenue

13.8 Qiagen
13.8.1 Overview
13.8.2 Recent Developments
13.8.3 Revenue

13.9 NeoGenomics Laboratories
13.9.1 Overview
13.9.2 Recent Developments
13.9.3 Revenue

13.10 Quest Diagnostics Inc.
13.10.1 Overview
13.10.2 Recent Developments
13.10.3 Revenue